98%
921
2 minutes
20
Background: The application of artificial intelligence (AI) in medicine has garnered significant attention in recent years, offering new possibilities for improving patient care across various domains. For herpes zoster, a viral infection caused by the reactivation of the varicella-zoster virus, AI technologies have shown remarkable potential in enhancing disease diagnosis, treatment, and management.
Objective: This study aims to investigate the current research status in the use of AI for herpes zoster, offering a comprehensive synthesis of existing advancements.
Methods: A systematic literature review was conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Three databases of Web of Science Core Collection, PubMed, and IEEE were searched to identify relevant studies on AI applications in herpes zoster research on November 17, 2023. Inclusion criteria were as follows: (1) research articles, (2) published in English, (3) involving actual AI applications, and (4) focusing on herpes zoster. Exclusion criteria comprised nonresearch articles, non-English papers, and studies only mentioning AI without application. Two independent clinicians screened the studies, with a third senior clinician resolving disagreements. In total, 26 articles were included. Data were extracted on AI task types; algorithms; data sources; data types; and clinical applications in diagnosis, treatment, and management.
Results: Trend analysis revealed an increasing annual interest in AI applications for herpes zoster. Hospital-derived data were the primary source (15/26, 57.7%), followed by public databases (6/26, 23.1%) and internet data (5/26, 19.2%). Medical images (9/26, 34.6%) and electronic medical records (7/26, 26.9%) were the most commonly used data types. Classification tasks (85.2%) dominated AI applications, with neural networks, particularly multilayer perceptron and convolutional neural networks being the most frequently used algorithms. AI applications were analyzed across three domains: (1) diagnosis, where mobile deep neural networks, convolutional neural network ensemble models, and mixed-scale attention-based models have improved diagnostic accuracy and efficiency; (2) treatment, where machine learning models, such as deep autoencoders combined with functional magnetic resonance imaging, electroencephalography, and clinical data, have enhanced treatment outcome predictions; and (3) management, where AI has facilitated case identification, epidemiological research, health care burden assessment, and risk factor exploration for postherpetic neuralgia and other complications.
Conclusions: Overall, this study provides a comprehensive overview of AI applications in herpes zoster from clinical, data, and algorithmic perspectives, offering valuable insights for future research in this rapidly evolving field. AI has significantly advanced herpes zoster research by enhancing diagnostic accuracy, predicting treatment outcomes, and optimizing disease management. However, several limitations exist, including potential omissions from excluding databases like Embase and Scopus, language bias due to the inclusion of only English publications, and the risk of subjective bias in study selection. Broader studies and continuous updates are needed to fully capture the scope of AI applications in herpes zoster in the future.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234400 | PMC |
http://dx.doi.org/10.2196/71970 | DOI Listing |
Clin Transl Oncol
September 2025
Ophthalmology Unit, Cannizzaro Hospital, 95126, Catania, Italy.
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life.
View Article and Find Full Text PDFPharmacoecon Open
September 2025
Department of Pharmacy, The Second Affiliated Hospital of Army Medical University, No.83 Xinqiao Central Street, Shapingba District, Chongqing, 400037, China.
Objective: Two vaccines against herpes zoster (HZ) are currently authorized for use in China: the adjuvanted recombinant zoster vaccine (RZV) and live-attenuated Zoster Vaccine Live (ZVL). The significant disparities in prices and efficacy between the two vaccines necessitate an evaluation of their relative value in order to make an informed choice. This study aimed to evaluate the comparative cost effectiveness of RZV, ZVL, and no vaccination for older adults at different ages from the societal perspective.
View Article and Find Full Text PDFAustralas J Dermatol
September 2025
Sydney School of Medicine, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
We report a case of zosteriform PCMZL presenting in a T3-T4 dermatomal distribution not previously described in the literature. Although the varicella zoster virus was not detected in this case, late diagnosis of the acute eruption of zoster or even preceding zoster 'sine herpete' cannot be excluded as antigenic triggers.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Family and Community Medicine, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Herpes zoster (HZ) is a reactivation of the varicella-zoster virus. It is a common infection, especially among patients with diabetes mellitus (DM). This study aimed to assess the awareness and uptake of the HZ vaccine, as well as their determinants, among patients with diabetes DM in the Aseer Region, Saudi Arabia.
View Article and Find Full Text PDFLupus Sci Med
September 2025
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background: SLE has increased risk of invasive pneumococcal disease due to immune dysregulation and immunosuppression. European Alliance of Associations for Rheumatology recommendations suggest sequential vaccination with conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, data on immunogenicity of sequential vaccination in SLE are limited.
View Article and Find Full Text PDF